Brought to you by 
Ori (now Replicor) seed round funds DNA replication technology
03 Aug 1999
Executive Summary
Ori Biotech, a Montreal start-up (since renamed Replicor Inc.; developing gene delivery systems), raised seed money of $450,000 from the venture capital firm T2C2 to fund development of platform technologies for regulating DNA replication.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ori (now Replicor) seed round funds DNA replication technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice